![Hoe eenvoudige semantiek onze AI-citaties met 642% verhoogde [Nieuwe resultaten]](https://www.pharmamarketeer.nl/wp-content/uploads/2026/01/719-370x300.jpg)
New indication boosts $1bn+ hopes for this year
Handelsvergunning voor middel tegen refractaire hypotensie
De Committee for Medicinal Products for Human Use (CHMP) heeft een positief advies gegeven over nieuwe handelsvergunningen voor een geneesmiddel.
US WorldMeds’ Myobloc injection gets US FDA approval for chronic sialorrhea
US WorldMeds, LLC, a specialty pharmaceutical company, announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for Myobloc (rimabotulinumtoxinB)
Ariën Breunis: ‘Content is king, strategie de aas’
Ariën Breunis spreekt op Content.19. Tijdens zijn workshop laat Breunis zien waarom content weliswaar king is, maar strategie de aas.
AstraZeneca announces update on phase III NEPTUNE trial of Imfinzi in combo with tremelimumab in stage IV NSCLC
AstraZeneca announced final overall survival (OS) results from the phase III NEPTUNE trial, a randomised, open─label, multi─centre, global trial of Imfinzi (durvalumab) in combination with tremelimumab, an anti─CTLA4
Retrophin’s phase 3 FORT study of fosmetpantotenate in patients with PKAN fails to meet primary endpoint
Retrophin Inc, a biopharmaceutical company specializing in identifying, developing and delivering life─changing therapies to people living with rare disease, announced that the phase 3 FORT study evaluating the safety
Satsuma Pharma begins phase 3 EMERGE trial of STS101 to treat migraine
Satsuma Pharmaceuticals, Inc, a clinical─stage biopharmaceutical company, announced dosing of the first patient in its phase 3 EMERGE efficacy trial of STS101 (dihydroergotamine (DHE) nasal powder) for the
Novo Nordisk’s Fiasp gets European approval to treat diabetes in adolescents & children
Novo Nordisk, a global healthcare company, announced that the European Commission has granted an extension of the indication for Fiasp (fast─acting insulin aspart), approving it for the treatment of diabetes in
Zydus Cadila gets US FDA approval for ranolazine ER tablets
Zydus Cadila has announced that it has received the final approval from the US Food and Drug Administration (FDA) to market ranolazine extended─release tablets (Ranexa), 500 mg and 1,000 mg. The drug is used to treat...
OxThera gets positive opinion from EMA on PIP for treatment of primary hyperoxaluria with Oxalobacter formigenes
OxThera AB, a privately─held biopharmaceutical company dedicated to improving the lives of people with primary hyperoxaluria (PH), announced that, based on a positive opinion from the Paediatric
Nieuwe kankermedicijnen in basispakket
Twee nieuwe soorten medicijnen tegen kanker komen in het basispakket. Minister Bruins heeft met de fabrikanten afspraken gemaakt over de prijs. Vanaf 1 september worden ze vergoed. Het gaat om durvalumab, een middel dat...
Event tracking: meet wat bezoekers op je pagina doen
Met event tracking in (Google) Analytics meet je wat bezoekers op je pagina’s aanklikken of doen. Ontdek hier hoe je dit inzet om je content te verbeteren. Als je content schrijft of ontwerpt, maak je allerlei keuzes...
AstraZeneca’s phase III DAPA─HF trial of Farxiga to treat heart failure meets primary endpoint
AstraZeneca announced positive results from the landmark phase III DAPA─HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically─significant and clinically─meaningful...
Nabriva Therapeutics’ Xenleta gets US FDA approval to treat community─acquired bacterial pneumonia
Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti─infective agents to treat serious infections, announced that the US Food and Drug Administration...
[column] Content met kwaliteit heeft geen marketingplan nodig
Nuttig verhaal op Frankwatching over een hogere ROI voor je content. Sander Kalkman gaat in op de vraag hoe je je content kunt aanbieden, het personaliseren van die content, het gebruik van visuals, de manieren om je...
[column] Merkdisruptie megatrend (8): Narcisme
Veel merken gaan de komende tijd verdwijnen. Het boek ‘Merkdisruptie’ van Frank Haveman, Jeroen Cremer en Richard Otto, brengt de oorzaken in kaart aan de hand van vijftien megatrends. Op Marketingtribune...
The Weekly Wrap: Data Makes Content Marketing Better
In less time than it takes the Kardashians to pick a fight, Robert Rose dishes all about data this week. He reveals a tactic missed by many, converses with a Content Marketer of the Year finalist, and shares a content...
EMA validates Gilead Sciences & Galapagos’ MAA for filgotinib to treat RA
Biopharmaceutical companies, Gilead Sciences and Galapagos NV announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults
